Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARBYCLOR vs ATACAND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Treatment of hypertension to lower blood pressure; lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
Treatment of hypertension,Treatment of heart failure (NYHA class II-IV and left ventricular systolic dysfunction) to reduce cardiovascular death and hospitalization for heart failure
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Azilsartan medoxomil is hydrolyzed to the active metabolite azilsartan; azilsartan is metabolized primarily by CYP2C9. Chlorthalidone is minimally metabolized, with most of the dose excreted unchanged in urine.
Candesartan is primarily metabolized by ester hydrolysis to its active metabolite, candesartan, and further undergoes O-deethylation by CYP2C9 (minor route).
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Azilsartan: >99% bound to serum albumin; chlorthalidone: approximately 75% bound to albumin and lipoproteins
High protein binding: >99%, primarily to serum albumin.
Azilsartan: approximately 16 L (0.2 L/kg) indicating limited extravascular distribution; chlorthalidone: approximately 3-4 L/kg (extensive tissue binding, particularly to erythrocytes)
Volume of distribution (Vd) is approximately 0.13 L/kg (mean 9 L). This low Vd indicates limited extravascular distribution, consistent with high plasma protein binding.
Azilsartan medoxomil: absolute bioavailability approximately 60% (oral); chlorthalidone: approximately 65% (oral)
Absolute oral bioavailability is approximately 15% (prodrug candesartan cilexetil is completely converted to active candesartan during absorption). Food does not affect bioavailability.
e GFR <30 m L/min/1.73m2: not recommended. No adjustment required for e GFR ≥30 m L/min/1.73m2.
No initial dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min (including dialysis), initiate at 4 mg once daily and titrate cautiously with monitoring.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): contraindicated. Child-Pugh Class C (severe): contraindicated.
For Child-Pugh Class A or B: initiate at 4 mg once daily and titrate cautiously. Child-Pugh Class C: not recommended (no data).
Not established; safety and efficacy in pediatric patients have not been studied.
For children ≥1 year and <6 years: 0.2-0.4 mg/kg/day once daily or divided twice daily; maximum 0.6 mg/kg/day (up to 32 mg/day). For children ≥6 years: 4-8 mg once initially; may increase to 16 mg once daily (or 32 mg daily in larger children).
Initiate with the lowest available dose (40 mg/12.5 mg) and titrate cautiously due to increased risk of hypotension and electrolyte disturbances.
Start at 4 mg once daily in patients ≥75 years; adjust based on blood pressure response and renal function (e.g., GFR <30 m L/min).
None
When pregnancy is detected, discontinue ATACAND as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause oligohydramnios, fetal renal dysfunction, and neonatal hypotension, hyperkalemia, and skull hypoplasia. Discontinue Edarbyclor as soon as possible when pregnancy is detected.,Hypotension: Correct volume- or salt-depleted patients prior to initiation; monitor for symptomatic hypotension.,Electrolyte disturbances: Chlorthalidone may cause hypokalemia, hyponatremia, and hypomagnesemia. Monitor electrolytes periodically.,Renal function deterioration: Monitor renal function in patients with renal artery stenosis, severe heart failure, or volume depletion.,Hyperkalemia: Risk increased with renal impairment, diabetes, or concomitant use of potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium.,Acute angle-closure glaucoma: Chlorthalidone, as a sulfonamide derivative, can cause idiosyncratic reaction leading to acute transient myopia and acute angle-closure glaucoma.,Exacerbation of systemic lupus erythematosus: Chlorthalidone may exacerbate or activate SLE.,Metabolic: Chlorthalidone may increase serum glucose, uric acid (precipitating gout), and decrease urinary calcium excretion.,Sulfonamide allergy: Chlorthalidone is a sulfonamide derivative; caution in patients with sulfonamide allergy.
Hypotension: Symptomatic hypotension may occur in volume-depleted patients or those with heart failure.,Hyperkalemia: Monitor serum potassium, especially in patients with renal impairment or on potassium-sparing diuretics.,Renal impairment: Use caution in patients with renal artery stenosis or severe renal impairment; monitor renal function.,Fetal/neonatal morbidity and mortality: As noted in black box warning.,Avoid use in patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney.
Anuria,Hypersensitivity to azilsartan medoxomil, chlorthalidone, or any component of the formulation,Concomitant use with aliskiren in patients with diabetes mellitus
Hypersensitivity to candesartan or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, salt substitutes) in excess due to risk of hyperkalemia. Avoid excessive salt intake. Grapefruit juice may alter drug metabolism; limit or avoid consumption. Alcohol may potentiate hypotensive effects.
No significant food interactions. Avoid potassium-rich foods (e.g., bananas, oranges, spinach, avocados) in large amounts if also taking potassium supplements or potassium-sparing diuretics. Salt substitutes containing potassium chloride should be used cautiously.
First trimester: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal renal dysplasia, oligohydramnios, and skull ossification defects when used in the second and third trimesters. There is no known risk of major malformations with first trimester exposure, but data are limited. Second and third trimesters: Use is contraindicated due to fetal renal dysfunction, oligohydramnios, pulmonary hypoplasia, limb contractures, and neonatal anuria, hypotension, and death. Azilsartan medoxomil (ARB) and chlorthalidone (thiazide diuretic) both affect RAS and fetal hemodynamics.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects, hypotension, anuria) due to direct renin-angiotensin system blockade. Risk of neonatal renal failure and hypotension if exposed after 20 weeks gestation.
No data on azilsartan medoxomil or chlorthalidone presence in human milk, effects on the breastfed infant, or milk production. Chlorthalidone is present in breast milk at low levels; M/P ratio unknown. Due to potential for adverse effects in the nursing infant (e.g., hypotension, renal impairment), alternative agents are recommended.
No data on candesartan in human milk; animal studies detect drug in milk. M/P ratio unknown. Avoid breastfeeding due to potential risk of neonatal hypotension and renal impairment.
EDARBYCLOR is not recommended in pregnancy, especially during second and third trimesters; if exposure occurs, discontinue as soon as possible. No specific dose adjustment studied; however, pregnancy can increase volume of distribution and clearance of some antihypertensives, but no data for this combination. Use is contraindicated after first trimester.
Avoid use in second and third trimesters due to fetotoxicity. If inadvertent exposure occurs, discontinue drug immediately. No dose adjustment recommended for first trimester use, but consider alternative antihypertensive agent throughout pregnancy.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil (an ARB) and chlorthalidone (a thiazide-like diuretic). Monitor renal function and electrolytes regularly due to risk of hypotension, hyperkalemia, and hyponatremia. Avoid use in patients with anuria or severe renal impairment (e GFR <30 m L/min). Chlorthalidone may exacerbate gout and hyperuricemia. Use caution in patients with hepatic impairment or diabetes.
ATACAND (candesartan cilexetil) is an angiotensin II receptor blocker (ARB) used primarily for hypertension and heart failure. Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation or dose adjustment. Avoid use in pregnancy (Category D). May cause angioedema; discontinue immediately if occurs. Dual blockade with ACE inhibitors or aliskiren increases risk of hypotension, hyperkalemia, and renal impairment.
Take this medication exactly as prescribed, usually once daily.,Avoid salt substitutes containing potassium unless approved by your doctor.,Drink plenty of fluids unless otherwise directed by your healthcare provider.,Report symptoms of low blood pressure (dizziness, fainting), electrolyte imbalance (muscle cramps, weakness), or kidney problems (decreased urination).,This drug may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Tell your doctor if you are pregnant or planning to become pregnant; this drug can cause fetal harm.,Limit alcohol intake as it may worsen side effects.,Do not stop taking this medication abruptly without consulting your doctor.
Take ATACAND exactly as prescribed, typically once daily with or without food.,Do not use if pregnant or planning pregnancy; consult doctor immediately if pregnancy occurs.,May cause dizziness or lightheadedness, especially during initial therapy; avoid driving until effects are known.,Avoid potassium supplements or salt substitutes containing potassium unless directed by healthcare provider.,Report signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to physician immediately.,Maintain adequate hydration and avoid dehydration (excessive sweating, vomiting, diarrhea).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDARBYCLOR vs ATACAND, answered by our medical review team.
EDARBYCLOR is a Angiotensin II Receptor Blocker/Thiazide Diuretic Combination that works by EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.. ATACAND is a Angiotensin II Receptor Blocker that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARBYCLOR and ATACAND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARBYCLOR is: One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.. The standard adult dose of ATACAND is: Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARBYCLOR and ATACAND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARBYCLOR is classified as Category C. First trimester: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal renal dysplasia, oligohydramnios, and skull ossification defects when used in the secon. ATACAND is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, sk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.